* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
FRA:5HB's PEG Ratio is ranked worse than 85.11% of 94
companies
in the Biotechnology industry
Industry Median: 2.03
vs FRA:5HB: 7.50
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Shanghai Haohai Biological Technology Co (FRA:5HB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Shanghai Haohai Biological Technology Co PEG Ratio Related Terms
Shanghai Haohai Biological Technology Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co PEG Ratio Chart
Shanghai Haohai Biological Technology Co Annual Data
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co PEG Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a PEG Ratio of 7.32 as of Jul. 06, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Shanghai Haohai Biological Technology Co and its competitors. This is 218% above median its historical median of 2.30. Over the past decade, Shanghai Haohai Biological Technology Co's PEG Ratio has ranged from 1.99 to 106.88. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #80 out of 94 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Shanghai Haohai Biological Technology Co's PEG Ratio too high?
Shanghai Haohai Biological Technology Co's current PEG Ratio of 7.32 is 218% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 106.88. The Biotechnology industry median PEG Ratio is 2.03. Shanghai Haohai Biological Technology Co's value of 7.32 is 260.6% above this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #80 out of 94 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #80 out of 94 companies for PEG Ratio. This places Shanghai Haohai Biological Technology Co in the lower half of its industry. The industry median PEG Ratio is 2.03. Shanghai Haohai Biological Technology Co's value of 7.32 is 260.6% above this benchmark. Historically, Shanghai Haohai Biological Technology Co's own PEG Ratio has ranged from 1.99 to 106.88 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 2.03, Shanghai Haohai Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 2.03, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current PEG Ratio of 7.32 is 260.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median PEG Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current PEG Ratio is 7.32, which is 218% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.59, compared to a current price of €1.72 — trading 33.6% below its estimated fair value. The current PEG Ratio is 7.32, which is 218% above median its 10-year median of 2.30 and 260.6% above the Biotechnology industry median of 2.03. Shanghai Haohai Biological Technology Co's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current PEG Ratio is 7.32 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.72 is trading 33.6% below its estimated GF Value™ of €2.59.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
PEG Ratio: 7.32 (218% above median its 10-year median of 2.30)
GF Value™: €2.59 vs. price of €1.72 (33.6% below fair value)
Industry Position: 260.6% above the Biotechnology median (#80 of 94)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Business Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
67GF Score
Get the complete analysis for FRA:5HB
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
